News | Balloon Catheter | April 04, 2024

FDA Announces Medos International Sàrl Recall of Cerenovus CEREBASE DA Guide Sheath due to Cracking of the Distal Catheter Shaft

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. 

April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling Cerenovus CEREBASE DA Guide Sheath due to a crack found in the far end of the catheter, where different parts of the catheter are joined together.

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.

Recalled Product 

  • Product Names: 
    • CERENOVUS CEREBASE DA Guide Sheath, Part Numbers:  
      • GS9070SD;
      • GS9080SD;  
      • GS9090SD;  
      • GS9095SD; 
    • Neurovascular guide catheter, single-use 
  • Product Codes: QJP 
  • Manufacturing Dates: July 7, 2023, and later
  • Distribution Dates: June 14, 2023, to December 14, 2023 
  • Devices Recalled in the U.S.: 1,343
  • Date Initiated by Firm: February 2, 2024 

Device Use 

The CEREBASE DA Guide Sheath is a neurovascular catheter. This type of catheter is commonly used in procedures where precise navigation and access to blood vessels in the brain are required. This catheter is designed to help deliver interventional devices into the blood vessels in the brain, allowing doctors to place devices like stents or coils, to treat neurovascular diseases and conditions. 

Reason for Recall

Medos International Sàrl is recalling the Cerenovus CEREBASE DA Guide Sheath due to complaints describing fractures of the distal catheter shaft. This is a crack found in the far end of the catheter that is placed in the vessels in the brain, where different parts of the catheter are joined together.

The use of the affected product may result in surgical procedural delay, vascular injury or hemorrhage, and in extreme rare occasions it may result in embolism.  
There have been 3 reported injuries.

There have been no reports of death.

Who May be Affected

  • Healthcare professionals who use the CEREBASE DA Guide Sheath in vascular procedures such as surgeries on the brain. 
  • People who are having procedures where precise navigation and access to blood vessels in the brain are required.

What to Do 

On February 2, 2024, Johnson & Johnson MedTech, on behalf of Medos, sent all affected customers an Urgent Medical Device Recall. 

The letter requested customers to: 

  • Examine inventory and quarantine any product subject to this recall.
  • Remove any product subject to this recall and communicate the issue to anyone who needs to be informed.
  • Contact any facility where affected products may have been forwarded to arrange their return.
  • Complete the Business Reply Form (BRF) confirming receipt of the notice and scan and email signed form to [email protected] or fax it to (305) 265-6889.
    • Attention Line: Cerebase FA2350411
  • Follow instructions in the letter and immediately call 1-844-483-3882 to return any inventory of CEREBASE DA Guide Sheath devices subject to the recall. To receive credit reimbursement, customers must return product subject to the recall.
    • Attention Line: Cerebase FA2350411

Contact Information  

Customers in the U.S. with questions about this recall should contact Medos at [email protected] 

Additional Resources  

How do I report a problem? 

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program using an online form, regular mail, or FAX. 


Related Content

News | FDA

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | FDA

July 29, 2024 — CorVascular, a leading producer of peripheral arterial disease (PAD) / peripheral vascular disease (PVD) ...

Home July 29, 2024
Home
News | FDA

July 2, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott has issued a correction for its ...

Home July 02, 2024
Home
News | FDA

June 18, 2024 — Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary ...

Home June 18, 2024
Home
News | FDA

June 17, 2024 — Elutia Inc., a pioneer in drug-eluting biomatrix products, today announced that its Antibiotic-Eluting ...

Home June 17, 2024
Home
News | FDA

June 13, 2024 — Xeltis, a leading developer of transformative implants that enable the natural creation of living and ...

Home June 13, 2024
Home
News | FDA

June 3, 2024 — Heuron, a specialized medical AI startup focused on brain and neurological disorders based in South Korea ...

Home June 03, 2024
Home
News | FDA

May 17, 2024 — Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has ...

Home May 17, 2024
Home
News | FDA

May 15, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling the HeartMate 3 LVAS by ...

Home May 15, 2024
Home
News | FDA

May 8, 2024 — The US Food and Drug Administration (FDA) is alerting health care providers and facilities about our ...

Home May 08, 2024
Home
Subscribe Now